Belite Bio, Inc (NASDAQ:BLTE – Get Rating) saw unusually-strong trading volume on Friday . Approximately 4,292 shares traded hands during trading, a decline of 88% from the previous session’s volume of 36,911 shares.The stock last traded at $37.00 and had previously closed at $38.98.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on BLTE shares. Benchmark started coverage on Belite Bio in a research note on Friday, July 1st. They set a “buy” rating and a $57.00 price target on the stock. HC Wainwright started coverage on Belite Bio in a research note on Monday, August 1st. They set a “buy” rating and a $58.00 price target on the stock.
Belite Bio Price Performance
The business’s 50 day moving average price is $33.28.
Institutional Inflows and Outflows
Belite Bio Company Profile
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial.
- Get a free copy of the StockNews.com research report on Belite Bio (BLTE)
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.